AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 672.45 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 79.23K shares, a 162.99% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 593.22K shares, a 137.79% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 22.99K shares, a 69.41% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 862.75K shares, a 28.52% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 1.17M shares, a 34.65% increase from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 865.48K shares, a 63.89% increase from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 528.10K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 79.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 672.45K shares 10-Q · filed 2026-08-05 | 695.43K shares derived: sum of 3 quarters · filed 2026-08-05 | 1.56M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 593.22K shares 10-Q · filed 2026-05-07 | 616.21K shares derived: sum of 2 quarters · filed 2026-05-07 | 1.48M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.51M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 22.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 885.74K shares derived: sum of 2 quarters · filed 2026-02-26 | 915.86K shares derived: sum of 3 quarters · filed 2026-02-26 | 1.17M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 862.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 892.88K shares derived: sum of 2 quarters · filed 2025-11-10 | 1.14M shares 10-Q · filed 2025-11-10 | 1.22M shares derived: sum of 4 quarters · filed 2025-11-10 |
| 2025-06-30 | 30.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 279.60K shares 10-Q · filed 2025-08-07 | 354.75K shares derived: sum of 3 quarters · filed 2025-08-07 | 1.03M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 249.47K shares 10-Q · filed 2025-05-08 | 324.63K shares derived: sum of 2 quarters · filed 2025-05-08 | 995.91K shares derived: sum of 3 quarters · filed 2025-05-08 | 1.09M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 75.15K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 746.43K shares derived: sum of 2 quarters · filed 2025-03-13 | 840.40K shares derived: sum of 3 quarters · filed 2025-03-13 | 865.48K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 671.28K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 765.25K shares derived: sum of 2 quarters · filed 2024-11-07 | 790.33K shares 10-Q · filed 2024-11-07 | 1.31M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 93.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 119.04K shares 10-Q · filed 2024-08-08 | 641.15K shares derived: sum of 3 quarters · filed 2024-08-08 | |
| 2024-03-31 | 25.07K shares 10-Q · filed 2024-05-09 | 547.18K shares derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2023-12-31 | 522.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 528.10K shares 10-K · filed 2024-03-14 | ||
| 2023-09-30 | 5.99K shares 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |